Can a simple chat with your pharmacist boost cancer pill adherence?

NCT ID NCT06989489

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients each—one group before the program and one group after at least six months in the program—using surveys to measure adherence and usability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Multilevel Adherence Intervention (behavioral counseling program)
What this could lead to
If effective, this program could become a standard tool to help cancer patients take their oral medications as prescribed, potentially improving treatment outcomes.
What could go wrong
This is a small, early-stage study comparing two groups at different times, not a randomized trial. The program may not work for everyone or may be hard to implement in other clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UNC Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27516, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.